Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
3.45 ^HKD	-1.43%		+0.88%	-5.48%

May. 09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT
Apr. 29	Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	CI

Abbisko Cayman Limited Announces Resignation of Yeh Richard as Chief Financial Officer, Effective April 28, 2022

April 26, 2022 at 06:19 pm EDT

Abbisko Cayman Limited announced that On April 27, 2022, Mr. Yeh Richard tendered his resignation as the Chief Financial Officer of the Company, with effect from April 28, 2022 due to his other commitments which require more of his dedication.

Latest news about Abbisko Cayman Limited

Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	May. 08	MT
Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	Apr. 29	CI
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation	Apr. 25	MT
Abbisko Cayman Limited Voluntary Announcement FGFR4 Inhibitor Irpagratinib Granted Odd by FDA	Apr. 24	CI
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	Apr. 24	CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	Apr. 09	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	Apr. 08	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	Apr. 08	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	Mar. 14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	Mar. 13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	Mar. 12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	Feb. 22	MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	Feb. 05	MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	Feb. 02	MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	Jan. 09	MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	Jan. 03	MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	Jan. 02	CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	Dec. 13	MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	Dec. 13	CI
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	Nov. 27	MT
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	Nov. 27	CI
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	Nov. 09	MT
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051	Nov. 08	CI
US FDA Green Lights Abbisko Subsidiary's Phase 1 Study for Anti-Tumor Drug	Nov. 07	MT

Chart Abbisko Cayman Limited

Duration

Period

More charts

Company Profile

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâs products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abbisko Cayman Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.19 CNY

Average target price

7.572 CNY

Spread / Average Target

+137.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABBISKO CAYMAN LIMITED	-5.48%	286M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs